Advanced Enzyme Technologies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 17.6x vs industry 50.2x)
- Virtually debt-free
- Regular dividends — yield 2.2%
- Near 52-week low — potential value zone (₹247)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ADVENZYMES · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.62% | 43.50% | 43.02% | 42.95% | 42.92% | 43.08% |
| FII | 22.54% | 23.01% | 12.03% | 12.63% | 12.57% | 11.90% |
| DII | 6.98% | 7.56% | 8.08% | 8.02% | 8.17% | 8.19% |
| Public | 26.88% | 25.95% | 36.87% | 36.40% | 36.31% | 36.82% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 1.20 Per Share
Interim Dividend - Rs 4 Per Share
Record: 16 May 2025
Dividend - Re 1.1 Per Share
Interim Dividend - Rs 4 Per Share
Record: 17 May 2024
Dividend - Re 1 Per Share
Record: 4 Aug 2023
Interim Dividend - Rs 4 Per Share
Record: 19 May 2023
Latest News
All newsSun Pharma R&D arm announces new drug trials
*Sun Pharma R&D arm announces new drug trials.* The company approved initiation of Phase II clinical trials for **SPARC-021**, a novel dermatological compound. Board also approved **₹75 crore** funding for R&D expansion. This move strengthens its innovation pipeline in specialty dermatology. 📊 *STOCKS:* $SPARC | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #R&D
Sun Pharma Advanced Research reports Q1 FY26 results.
*Sun Pharma Advanced Research reports Q1 FY26 results.* The company has released its unaudited financial results for the quarter ended June 30, 2026. Key figures include revenue of **₹128.4 crore** and net profit of **₹22.1 crore**. Performance reflects steady growth in core R&D operations. 📊 *STOCKS:* $SPARC | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
TCS partners with Anthropic for enterprise AI solutions
*TCS partners with Anthropic for enterprise AI solutions*. TCS has launched a global premier partnership with AI firm Anthropic to scale enterprise AI solutions. The collaboration aims to deliver advanced AI-driven services to clients worldwide, boosting TCS's positioning in the AI space. This strategic move strengthens TCS’s AI capabilities and client offerings. 📊 *STOCKS:* TCS | 🏢 *SECTOR:* IT | #HIGHIMPACT #AI
India approves $22B defence deals with 82% local sourcing
*India approves $22B defence deals with 82% local sourcing.* The move boosts domestic defence manufacturing under the 'Make in India' initiative. Projects include advanced weapons systems and modernization of armed forces. Local suppliers and PSUs in defence space may benefit. 📊 *STOCKS:* | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Defence
India approves $22.2 billion in defence acquisitions
*India approves $22.2 billion in defence acquisitions.* This marks one of the largest defence capex clearances, boosting domestic manufacturing under the 'Make in India' initiative. The move is expected to benefit public and private defence players, with long-term implications for the sector. The approved proposals include advanced missile systems and naval vessels. 📊 *STOCKS:* | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Defence
IMF forecasts India's 2027 growth at 7%.
*IMF projects India will grow at 7% in 2027*, far outpacing advanced economies at **1.8%**. This reinforces India’s position as a global growth leader. Strong domestic demand and investment drive the outlook. Rising inflows into Indian markets likely. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #HIGHIMPACT #IMF
Tata Group, Shapoorji Pallonji in talks for Tata Sons stake swap
*Tata Group and Shapoorji Pallonji are in advanced talks for a share swap involving a stake in Tata Sons.* The proposed deal could reshape ownership in the **₹25-lakh crore** conglomerate. Details including valuation and equity exchange are under discussion. Final terms may impact group stock valuations and investor sentiment. 📊 *STOCKS:* | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Tata
Persistent Systems eyes major acquisition
*Persistent Systems eyes major acquisition* — The IT firm is in advanced talks for a significant buyout, potentially exceeding ₹500Cr. This move signals aggressive expansion and vertical integration. A deal could boost scale and global delivery capabilities. 📊 *STOCKS:* PERSISTENT | 🏢 *SECTOR:* IT | #HIGHIMPACT #Acquisition
Hyundai launches BAYON SUV at ₹9.99L, targets future mobility segment
*Hyundai launches BAYON SUV at ₹9.99L, targets future mobility segment* — Hyundai Motor India unveiled the new BAYON SUV priced at **₹9.99 lakh**, marking its entry into the compact electric SUV segment. The launch aims to strengthen Hyundai’s position in the growing EV market with advanced tech features. Priced competitively, the BAYON could drive volume sales and market share gains. 📊 *STOCKS:* $HYUNDAI | 🏢 *SECTOR:* Auto | #MEDIUMIMPACT #NewLaunch
Krsnaa Diagnostics partners with AZmed for AI radiology platform
*Krsnaa Diagnostics partners with AZmed for AI radiology platform* — Krsnaa Diagnostics has announced a strategic collaboration with global radiology AI firm AZmed to develop an AI-powered platform for enhanced reporting efficiency and scalable growth. The move aims to improve diagnostic accuracy and expand service capacity using advanced AI tools. This partnership could strengthen Krsnaa’s competitive edge in the healthcare diagnostics space. 📊 *STOCKS:* $KRSA | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #AI
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹172 Cr 7.0% | ₹185 Cr 0.5% | ₹186 Cr 11.4% | ₹167 Cr 1.2% | ₹169 Cr 15.8% | ₹146 Cr 5.8% | ₹155 Cr 1.9% | ₹158 Cr |
| Op. Profit | ₹49 Cr 18.3% | ₹60 Cr 7.1% | ₹56 Cr 21.7% | ₹46 Cr 16.4% | ₹55 Cr 31.0% | ₹42 Cr 17.6% | ₹51 Cr 7.3% | ₹55 Cr |
| OPM | 29.0% 12.1% | 33.0% 10.0% | 30.0% 11.1% | 27.0% 18.2% | 33.0% 13.8% | 29.0% 12.1% | 33.0% 5.7% | 35.0% |
| Net Profit | ₹43 Cr 4.4% | ₹45 Cr 12.5% | ₹40 Cr 48.1% | ₹27 Cr 30.8% | ₹39 Cr 18.2% | ₹33 Cr 5.7% | ₹35 Cr 16.7% | ₹30 Cr |
| EPS (₹) | 3.8 1.8% | 3.87 8.4% | 3.57 50.6% | 2.37 29.7% | 3.37 14.6% | 2.94 3.6% | 3.05 20.6% | 2.53 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹746 Cr 17.1% | ₹637 Cr 2.1% | ₹624 Cr 15.3% | ₹541 Cr 2.3% | ₹529 Cr 5.4% | ₹502 Cr 13.1% | ₹444 Cr 5.7% | ₹420 Cr 7.4% | ₹391 Cr 18.8% | ₹329 Cr |
| Expenses | ₹517 Cr 17.2% | ₹441 Cr 5.5% | ₹418 Cr 9.4% | ₹382 Cr 16.8% | ₹327 Cr 21.6% | ₹269 Cr 11.6% | ₹241 Cr 2.1% | ₹236 Cr 4.4% | ₹226 Cr 27.7% | ₹177 Cr |
| Op. Profit | ₹229 Cr 16.8% | ₹196 Cr 4.9% | ₹206 Cr 30.4% | ₹158 Cr 22.2% | ₹203 Cr 12.5% | ₹232 Cr 14.3% | ₹203 Cr 10.3% | ₹184 Cr 11.5% | ₹165 Cr 8.6% | ₹152 Cr |
| OPM | 31.0% 0.0% | 31.0% 6.1% | 33.0% 13.8% | 29.0% 23.7% | 38.0% 17.4% | 46.0% 0.0% | 46.0% 4.5% | 44.0% 4.8% | 42.0% 8.7% | 46.0% |
| Other Income | ₹46 Cr 39.4% | ₹33 Cr 57.1% | ₹21 Cr 0.0% | ₹21 Cr 250.0% | ₹6 Cr 33.3% | ₹9 Cr 50.0% | ₹6 Cr 20.0% | ₹5 Cr 400.0% | ₹1 Cr 66.7% | ₹3 Cr |
| Interest | ₹3 Cr 40.0% | ₹5 Cr 25.0% | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 20.0% | ₹5 Cr 44.4% | ₹9 Cr 125.0% | ₹4 Cr |
| Depreciation | ₹40 Cr 8.1% | ₹37 Cr 5.7% | ₹35 Cr 0.0% | ₹35 Cr 0.0% | ₹35 Cr 25.0% | ₹28 Cr 7.7% | ₹26 Cr 23.8% | ₹21 Cr 16.7% | ₹18 Cr 38.5% | ₹13 Cr |
| PBT | ₹233 Cr 24.6% | ₹187 Cr 0.5% | ₹188 Cr 34.3% | ₹140 Cr 18.1% | ₹171 Cr 18.6% | ₹210 Cr 17.3% | ₹179 Cr 10.5% | ₹162 Cr 16.5% | ₹139 Cr 1.5% | ₹137 Cr |
| Tax % | 25.0% 10.7% | 28.0% 3.7% | 27.0% 3.8% | 26.0% 7.1% | 28.0% 0.0% | 28.0% 7.7% | 26.0% 7.1% | 28.0% 15.2% | 33.0% 3.1% | 32.0% |
| Net Profit | ₹174 Cr 29.9% | ₹134 Cr 2.2% | ₹137 Cr 31.7% | ₹104 Cr 16.1% | ₹124 Cr 17.9% | ₹151 Cr 13.5% | ₹133 Cr 14.7% | ₹116 Cr 23.4% | ₹94 Cr 1.1% | ₹93 Cr |
| EPS (₹) | 15.07 28.6% | 11.72 1.7% | 11.92 26.1% | 9.45 11.7% | 10.7 18.3% | 13.09 13.0% | 11.58 16.4% | 9.95 23.3% | 8.07 1.6% | 8.2 |
| Div Payout | 9.0% 79.5% | 44.0% 2.3% | 43.0% 290.9% | 11.0% 22.2% | 9.0% 28.6% | 7.0% 40.0% | 5.0% 16.7% | 6.0% 0.0% | 6.0% 20.0% | 5.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr 0.0% | ₹22 Cr |
| Reserves | ₹1.5K Cr 4.6% | ₹1.4K Cr 7.4% | ₹1.3K Cr 7.3% | ₹1.2K Cr 13.8% | ₹1.1K Cr 12.4% | ₹948 Cr 16.0% | ₹817 Cr 24.4% | ₹657 Cr 22.3% | ₹537 Cr 21.5% | ₹442 Cr |
| Borrowings | ₹35 Cr 10.3% | ₹39 Cr 17.0% | ₹47 Cr 38.2% | ₹34 Cr 2.9% | ₹35 Cr 52.2% | ₹23 Cr 17.9% | ₹28 Cr 20.0% | ₹35 Cr 47.8% | ₹67 Cr 24.1% | ₹54 Cr |
| Other Liabilities | ₹173 Cr 14.6% | ₹151 Cr 0.7% | ₹150 Cr 5.6% | ₹142 Cr 3.6% | ₹137 Cr 10.5% | ₹153 Cr 47.1% | ₹104 Cr 14.3% | ₹91 Cr 10.8% | ₹102 Cr 56.9% | ₹65 Cr |
| Total Liabilities | ₹1.7K Cr 5.0% | ₹1.6K Cr 5.9% | ₹1.5K Cr 7.8% | ₹1.4K Cr 12.0% | ₹1.3K Cr 9.9% | ₹1.1K Cr 18.0% | ₹971 Cr 20.6% | ₹805 Cr 10.7% | ₹727 Cr 24.7% | ₹583 Cr |
Assets | ||||||||||
| Fixed Assets | ₹683 Cr 0.6% | ₹679 Cr 4.5% | ₹650 Cr 0.2% | ₹649 Cr 4.8% | ₹619 Cr 3.0% | ₹601 Cr 6.7% | ₹563 Cr 13.7% | ₹495 Cr 0.8% | ₹491 Cr 16.6% | ₹421 Cr |
| CWIP | ₹31 Cr 40.9% | ₹22 Cr 46.3% | ₹41 Cr 86.4% | ₹22 Cr 46.7% | ₹15 Cr 50.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 9.1% | ₹11 Cr 37.5% | ₹8 Cr |
| Investments | ₹529 Cr 10.2% | ₹480 Cr 19.1% | ₹403 Cr 11.9% | ₹360 Cr 252.9% | ₹102 Cr 15.7% | ₹121 Cr 2.4% | ₹124 Cr 11.7% | ₹111 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹449 Cr 4.4% | ₹430 Cr 0.7% | ₹427 Cr 12.4% | ₹380 Cr 27.5% | ₹524 Cr 26.9% | ₹413 Cr 50.2% | ₹275 Cr 46.3% | ₹188 Cr 16.8% | ₹226 Cr 47.7% | ₹153 Cr |
| Total Assets | ₹1.7K Cr 5.0% | ₹1.6K Cr 5.9% | ₹1.5K Cr 7.8% | ₹1.4K Cr 12.0% | ₹1.3K Cr 9.9% | ₹1.1K Cr 18.0% | ₹971 Cr 20.6% | ₹805 Cr 10.7% | ₹727 Cr 24.7% | ₹583 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹142 Cr 0.7% | ₹141 Cr 0.7% | ₹140 Cr 14.8% | ₹122 Cr 25.2% | ₹163 Cr 15.6% | ₹141 Cr 9.3% | ₹129 Cr 11.2% | ₹116 Cr 8.4% | ₹107 Cr 15.1% | ₹93 Cr |
| Investing CF | ₹-89 Cr 36.9% | ₹-65 Cr 77.3% | ₹-286 Cr 14400.0% | ₹2 Cr 107.4% | ₹-27 Cr 37.2% | ₹-43 Cr 65.3% | ₹-124 Cr 106.7% | ₹-60 Cr 0.0% | ₹-60 Cr 500.0% | ₹-10 Cr |
| Financing CF | ₹-73 Cr 23.7% | ₹-59 Cr 126.9% | ₹-26 Cr 45.8% | ₹-48 Cr 84.6% | ₹-26 Cr 33.3% | ₹-39 Cr 9.3% | ₹-43 Cr 2050.0% | ₹-2 Cr 96.9% | ₹-65 Cr 3.2% | ₹-63 Cr |
| Net Cash Flow | ₹-20 Cr 217.6% | ₹17 Cr 109.9% | ₹-171 Cr 328.0% | ₹75 Cr 31.2% | ₹109 Cr 81.7% | ₹60 Cr 257.9% | ₹-38 Cr 170.4% | ₹54 Cr 400.0% | ₹-18 Cr 185.7% | ₹21 Cr |
| Free Cash Flow | ₹108 Cr 14.9% | ₹94 Cr 7.8% | ₹102 Cr 7.4% | ₹95 Cr 33.6% | ₹143 Cr 58.9% | ₹90 Cr 22.4% | ₹116 Cr 10.5% | ₹105 Cr 8.2% | ₹97 Cr 10.2% | ₹88 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66d 13.8% | 58d 14.7% | 68d 11.5% | 61d 3.2% | 63d 3.3% | 61d 19.6% | 51d 7.3% | 55d 0.0% | 55d 5.8% | 52d |
| Inventory Days | 378d 0.8% | 375d 9.3% | 343d 14.7% | 402d 16.2% | 346d 4.2% | 361d 0.6% | 363d 7.1% | 339d 3.7% | 352d 1.7% | 358d |
| Days Payable | 41d 2.5% | 40d 40.3% | 67d 11.7% | 60d 7.1% | 56d 30.2% | 43d 6.5% | 46d 41.0% | 78d 36.8% | 57d 16.2% | 68d |
| Cash Conv. Cycle | 403d 2.5% | 393d 14.2% | 344d 14.9% | 404d 14.4% | 353d 6.9% | 379d 2.7% | 369d 17.1% | 315d 10.3% | 351d 2.6% | 342d |
| Working Capital Days | 112d 9.8% | 102d 6.4% | 109d 6.0% | 116d 23.4% | 94d 4.4% | 90d 25.0% | 72d 53.2% | 47d 38.2% | 76d 2433.3% | 3d |
| ROCE | 13.0% 13.3% | 15.0% 25.0% | 12.0% 25.0% | 16.0% 27.3% | 22.0% 0.0% | 22.0% 8.3% | 24.0% 4.0% | 25.0% 19.4% | 31.0% 13.9% | 36.0% |
Source: Screener.in · Lower days = better efficiency
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
HealthcarePharmaceuticals & Biotechnology